ID   EPHB6_HUMAN             Reviewed;        1021 AA.
AC   O15197; A4D2I7; A8CDT5; D3DXD3; Q2TB23; Q2TB24;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   20-APR-2010, sequence version 4.
DT   12-OCT-2022, entry version 218.
DE   RecName: Full=Ephrin type-B receptor 6;
DE   AltName: Full=HEP;
DE   AltName: Full=Tyrosine-protein kinase-defective receptor EPH-6;
DE   Flags: Precursor;
GN   Name=EPHB6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=9207182; DOI=10.1006/bbrc.1997.6812;
RA   Matsuoka H., Iwata N., Ito M., Shimoyama M., Nagata A., Chihara K.,
RA   Takai S., Matsui T.;
RT   "Expression of a kinase-defective Eph-like receptor in the normal human
RT   brain.";
RL   Biochem. Biophys. Res. Commun. 235:487-492(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-122; ARG-282; ALA-324
RP   AND GLN-499.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 16-1021 (ISOFORM 3).
RX   PubMed=18425388;
RA   Jin M., Komohara Y., Shichijo S., Harada M., Yamanaka R., Miyamoto S.,
RA   Nikawa J., Itoh K., Yamada A.;
RT   "Identification of EphB6 variant-derived epitope peptides recognized by
RT   cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients.";
RL   Oncol. Rep. 19:1277-1283(2008).
RN   [8]
RP   PROTEIN SEQUENCE OF 32-46.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [9]
RP   INTERACTION WITH CBL AND EPHB1, AND PHOSPHORYLATION.
RX   PubMed=11713248; DOI=10.1074/jbc.m108011200;
RA   Freywald A., Sharfe N., Roifman C.M.;
RT   "The kinase-null EphB6 receptor undergoes transphosphorylation in a complex
RT   with EphB1.";
RL   J. Biol. Chem. 277:3823-3828(2002).
RN   [10]
RP   FUNCTION.
RX   PubMed=12517763; DOI=10.1074/jbc.m208179200;
RA   Freywald A., Sharfe N., Rashotte C., Grunberger T., Roifman C.M.;
RT   "The EphB6 receptor inhibits JNK activation in T lymphocytes and modulates
RT   T cell receptor-mediated responses.";
RL   J. Biol. Chem. 278:10150-10156(2003).
RN   [11]
RP   FUNCTION, INTERACTION WITH FYN, AND PHOSPHORYLATION.
RX   PubMed=15955811; DOI=10.1074/jbc.m500010200;
RA   Matsuoka H., Obama H., Kelly M.L., Matsui T., Nakamoto M.;
RT   "Biphasic functions of the kinase-defective Ephb6 receptor in cell adhesion
RT   and migration.";
RL   J. Biol. Chem. 280:29355-29363(2005).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=18754880; DOI=10.1111/j.1349-7006.2008.00866.x;
RA   Jin M., Komohara Y., Shichijo S., Yamanaka R., Nikawa J., Itoh K.,
RA   Yamada A.;
RT   "Erythropoietin-producing hepatocyte B6 variant-derived peptides with the
RT   ability to induce glioma-reactive cytotoxic T lymphocytes in human
RT   leukocyte antigen-A2+ glioma patients.";
RL   Cancer Sci. 99:1656-1662(2008).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=19234485; DOI=10.1038/onc.2009.18;
RA   Fox B.P., Kandpal R.P.;
RT   "EphB6 receptor significantly alters invasiveness and other phenotypic
RT   characteristics of human breast carcinoma cells.";
RL   Oncogene 28:1706-1713(2009).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-360; PRO-603; GLN-719 AND GLY-930.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-122; THR-170; VAL-221; HIS-282;
RP   GLN-309; ALA-324; LEU-332; VAL-662; SER-743; HIS-813; LYS-875 AND VAL-993.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Kinase-defective receptor for members of the ephrin-B family.
CC       Binds to ephrin-B1 and ephrin-B2. Modulates cell adhesion and migration
CC       by exerting both positive and negative effects upon stimulation with
CC       ephrin-B2. Inhibits JNK activation, T-cell receptor-induced IL-2
CC       secretion and CD25 expression upon stimulation with ephrin-B2.
CC       {ECO:0000269|PubMed:12517763, ECO:0000269|PubMed:15955811}.
CC   -!- SUBUNIT: Interacts with CBL and EPHB1. Interacts with FYN; this
CC       interaction takes place in a ligand-independent manner.
CC       {ECO:0000269|PubMed:11713248, ECO:0000269|PubMed:15955811}.
CC   -!- INTERACTION:
CC       O15197; P08238: HSP90AB1; NbExp=3; IntAct=EBI-714076, EBI-352572;
CC       O15197-2; O95994: AGR2; NbExp=3; IntAct=EBI-10182490, EBI-712648;
CC       O15197-2; Q8WXK4-2: ASB12; NbExp=3; IntAct=EBI-10182490, EBI-18394052;
CC       O15197-2; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-10182490, EBI-2548012;
CC       O15197-2; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-10182490, EBI-742054;
CC       O15197-2; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-10182490, EBI-747204;
CC       O15197-2; Q0VD86: INCA1; NbExp=8; IntAct=EBI-10182490, EBI-6509505;
CC       O15197-2; P35548: MSX2; NbExp=3; IntAct=EBI-10182490, EBI-6447480;
CC       O15197-2; Q5VT66: MTARC1; NbExp=3; IntAct=EBI-10182490, EBI-11903927;
CC       O15197-2; Q9GZT8: NIF3L1; NbExp=3; IntAct=EBI-10182490, EBI-740897;
CC       O15197-2; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-10182490, EBI-945833;
CC       O15197-2; P78424: POU6F2; NbExp=3; IntAct=EBI-10182490, EBI-12029004;
CC       O15197-2; O14744: PRMT5; NbExp=3; IntAct=EBI-10182490, EBI-351098;
CC       O15197-2; Q04864: REL; NbExp=3; IntAct=EBI-10182490, EBI-307352;
CC       O15197-2; Q04864-2: REL; NbExp=3; IntAct=EBI-10182490, EBI-10829018;
CC       O15197-2; Q99081-3: TCF12; NbExp=3; IntAct=EBI-10182490, EBI-11952764;
CC       O15197-2; P15884: TCF4; NbExp=3; IntAct=EBI-10182490, EBI-533224;
CC       O15197-2; P15884-3: TCF4; NbExp=3; IntAct=EBI-10182490, EBI-13636688;
CC       O15197-2; Q96M29: TEKT5; NbExp=3; IntAct=EBI-10182490, EBI-10239812;
CC       O15197-2; Q96RU7: TRIB3; NbExp=3; IntAct=EBI-10182490, EBI-492476;
CC       O15197-2; Q9HCM9: TRIM39; NbExp=3; IntAct=EBI-10182490, EBI-739510;
CC       O15197-2; Q9HCM9-2: TRIM39; NbExp=5; IntAct=EBI-10182490, EBI-11523450;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O15197-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15197-2; Sequence=VSP_037496;
CC       Name=3; Synonyms=EphB6v;
CC         IsoId=O15197-3; Sequence=VSP_037497, VSP_037498;
CC   -!- TISSUE SPECIFICITY: Expressed in brain. Expressed in non invasive
CC       breast carcinoma cell lines (at protein level). Strong expression in
CC       brain and pancreas, and weak expression in other tissues, such as
CC       heart, placenta, lung, liver, skeletal muscle and kidney. Expressed in
CC       breast non invasive tumors but not in metastatic lesions. Isoform 3 is
CC       expressed in cell lines of glioblastomas, anaplastic astrocytomas,
CC       gliosarcomas and astrocytomas. Isoform 3 is not detected in normal
CC       tissues. {ECO:0000269|PubMed:18754880, ECO:0000269|PubMed:19234485,
CC       ECO:0000269|PubMed:9207182}.
CC   -!- DOMAIN: The protein kinase domain is predicted to be catalytically
CC       inactive. Its extracellular domain is capable of promoting cell
CC       adhesion and migration in response to low concentrations of ephrin-B2,
CC       but its cytoplasmic domain is essential for cell repulsion and
CC       inhibition of migration induced by high concentrations of ephrin-B2.
CC   -!- PTM: Ligand-binding increases phosphorylation on tyrosine residues.
CC       Phosphorylation on tyrosine residues is mediated by
CC       transphosphorylation by the catalytically active EPHB1 in a ligand-
CC       independent manner. Tyrosine phosphorylation of the receptor may act as
CC       a switch on the functional transition from cell adhesion/attraction to
CC       de-adhesion/repulsion. {ECO:0000269|PubMed:11713248,
CC       ECO:0000269|PubMed:15955811}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD03058.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAI10608.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAP20939.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA21560.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=EAL23775.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAW51902.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ephb6/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EPHB6ID40471ch7q34.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D83492; BAA21560.1; ALT_INIT; mRNA.
DR   EMBL; AY280502; AAP20939.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF107256; AAD03058.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AC104597; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236959; EAL23775.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471198; EAW51900.1; -; Genomic_DNA.
DR   EMBL; CH471198; EAW51901.1; -; Genomic_DNA.
DR   EMBL; CH471198; EAW51902.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471198; EAW51903.1; -; Genomic_DNA.
DR   EMBL; BC051028; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC110606; AAI10607.1; -; mRNA.
DR   EMBL; BC110607; AAI10608.2; ALT_INIT; mRNA.
DR   EMBL; EU054308; ABV55388.1; -; mRNA.
DR   PIR; JC5526; JC5526.
DR   RefSeq; NP_001267724.2; NM_001280795.2.
DR   RefSeq; NP_004436.4; NM_004445.5.
DR   PDB; 7K7J; X-ray; 3.00 A; A=33-578.
DR   PDBsum; 7K7J; -.
DR   AlphaFoldDB; O15197; -.
DR   SMR; O15197; -.
DR   BioGRID; 108365; 43.
DR   IntAct; O15197; 73.
DR   MINT; O15197; -.
DR   STRING; 9606.ENSP00000481994; -.
DR   BindingDB; O15197; -.
DR   ChEMBL; CHEMBL5836; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; O15197; -.
DR   GlyGen; O15197; 1 site.
DR   iPTMnet; O15197; -.
DR   PhosphoSitePlus; O15197; -.
DR   BioMuta; EPHB6; -.
DR   jPOST; O15197; -.
DR   MassIVE; O15197; -.
DR   PaxDb; O15197; -.
DR   PeptideAtlas; O15197; -.
DR   PRIDE; O15197; -.
DR   ProteomicsDB; 48502; -. [O15197-1]
DR   ProteomicsDB; 48503; -. [O15197-2]
DR   ProteomicsDB; 48504; -. [O15197-3]
DR   ABCD; O15197; 7 sequenced antibodies.
DR   DNASU; 2051; -.
DR   GeneID; 2051; -.
DR   KEGG; hsa:2051; -.
DR   CTD; 2051; -.
DR   DisGeNET; 2051; -.
DR   GeneCards; EPHB6; -.
DR   HGNC; HGNC:3396; EPHB6.
DR   MIM; 602757; gene.
DR   neXtProt; NX_O15197; -.
DR   PharmGKB; PA27828; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   InParanoid; O15197; -.
DR   OrthoDB; 933071at2759; -.
DR   PhylomeDB; O15197; -.
DR   TreeFam; TF314013; -.
DR   PathwayCommons; O15197; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; O15197; -.
DR   BioGRID-ORCS; 2051; 7 hits in 1011 CRISPR screens.
DR   ChiTaRS; EPHB6; human.
DR   GeneWiki; EPHB6; -.
DR   GenomeRNAi; 2051; -.
DR   Pharos; O15197; Tchem.
DR   PRO; PR:O15197; -.
DR   Proteomes; UP000005640; Unplaced.
DR   RNAct; O15197; protein.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005003; F:ephrin receptor activity; TAS:ProtInc.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0021952; P:central nervous system projection neuron axonogenesis; IBA:GO_Central.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF07699; Ephrin_rec_like; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Direct protein sequencing;
KW   Glycoprotein; Membrane; Nucleotide-binding; Receptor; Reference proteome;
KW   Repeat; Secreted; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..31
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           32..1021
FT                   /note="Ephrin type-B receptor 6"
FT                   /id="PRO_0000016837"
FT   TOPO_DOM        32..594
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        595..615
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        616..1021
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          33..237
FT                   /note="Eph LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00883"
FT   DOMAIN          369..486
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          487..582
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          670..919
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          948..1012
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   REGION          163..182
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           1019..1021
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        163..179
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         676..684
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   CARBOHYD        480
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         16..292
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037496"
FT   VAR_SEQ         487..540
FT                   /note="VPSAVPVVHQVSRASNSITVSWPQPDQTNGNILDYQLRYYDQAEDESHSFTL
FT                   TS -> GELFSLAFRIPCLRSFEPPSLLLISSLVHPCRPPLKADPAPRDSYPHNNFPFA
FT                   L (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18425388"
FT                   /id="VSP_037497"
FT   VAR_SEQ         541..1021
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18425388"
FT                   /id="VSP_037498"
FT   VARIANT         122
FT                   /note="G -> S (in dbSNP:rs8177173)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.2"
FT                   /id="VAR_019139"
FT   VARIANT         170
FT                   /note="S -> T"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042190"
FT   VARIANT         221
FT                   /note="A -> V"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042191"
FT   VARIANT         282
FT                   /note="P -> H"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042192"
FT   VARIANT         282
FT                   /note="P -> R (in dbSNP:rs8177143)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_019140"
FT   VARIANT         309
FT                   /note="R -> Q (in dbSNP:rs55728646)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042193"
FT   VARIANT         324
FT                   /note="S -> A (in dbSNP:rs8177146)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.2"
FT                   /id="VAR_019141"
FT   VARIANT         332
FT                   /note="S -> L (in dbSNP:rs35189999)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042194"
FT   VARIANT         360
FT                   /note="D -> N (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036091"
FT   VARIANT         499
FT                   /note="R -> Q (in dbSNP:rs8177175)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_019142"
FT   VARIANT         603
FT                   /note="A -> P (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036092"
FT   VARIANT         662
FT                   /note="A -> V (in dbSNP:rs35984674)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042195"
FT   VARIANT         719
FT                   /note="R -> Q (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036093"
FT   VARIANT         743
FT                   /note="P -> S (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042196"
FT   VARIANT         813
FT                   /note="R -> H"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042197"
FT   VARIANT         875
FT                   /note="E -> K (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042198"
FT   VARIANT         930
FT                   /note="D -> G (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036094"
FT   VARIANT         993
FT                   /note="I -> V"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042199"
FT   STRAND          34..42
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          49..52
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          55..62
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          64..66
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          68..74
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   HELIX           76..78
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          88..91
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          101..112
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   HELIX           114..116
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          117..119
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   TURN            121..123
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          126..139
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   TURN            141..144
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          148..150
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          153..159
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          190..192
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          195..202
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          206..217
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          219..229
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          235..237
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          240..242
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          256..259
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          283..286
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          292..296
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          305..308
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   TURN            309..312
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          313..316
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          325..328
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          342..344
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          374..380
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          382..390
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          402..409
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          414..416
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   TURN            418..420
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          437..447
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          456..463
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          465..469
FT                   /evidence="ECO:0007829|PDB:7K7J"
FT   STRAND          476..481
FT                   /evidence="ECO:0007829|PDB:7K7J"
SQ   SEQUENCE   1021 AA;  110700 MW;  BF1D4D9BE34358A5 CRC64;
     MATEGAAQLG NRVAGMVCSL WVLLLVSSVL ALEEVLLDTT GETSEIGWLT YPPGGWDEVS
     VLDDQRRLTR TFEACHVAGA PPGTGQDNWL QTHFVERRGA QRAHIRLHFS VRACSSLGVS
     GGTCRETFTL YYRQAEEPDS PDSVSSWHLK RWTKVDTIAA DESFPSSSSS SSSSSSAAWA
     VGPHGAGQRA GLQLNVKERS FGPLTQRGFY VAFQDTGACL ALVAVRLFSY TCPAVLRSFA
     SFPETQASGA GGASLVAAVG TCVAHAEPEE DGVGGQAGGS PPRLHCNGEG KWMVAVGGCR
     CQPGYQPARG DKACQACPRG LYKSSAGNAP CSPCPARSHA PNPAAPVCPC LEGFYRASSD
     PPEAPCTGPP SAPQELWFEV QGSALMLHWR LPRELGGRGD LLFNVVCKEC EGRQEPASGG
     GGTCHRCRDE VHFDPRQRGL TESRVLVGGL RAHVPYILEV QAVNGVSELS PDPPQAAAIN
     VSTSHEVPSA VPVVHQVSRA SNSITVSWPQ PDQTNGNILD YQLRYYDQAE DESHSFTLTS
     ETNTATVTQL SPGHIYGFQV RARTAAGHGP YGGKVYFQTL PQGELSSQLP ERLSLVIGSI
     LGALAFLLLA AITVLAVVFQ RKRRGTGYTE QLQQYSSPGL GVKYYIDPST YEDPCQAIRE
     LAREVDPAYI KIEEVIGTGS FGEVRQGRLQ PRGRREQTVA IQALWAGGAE SLQMTFLGRA
     AVLGQFQHPN ILRLEGVVTK SRPLMVLTEF MELGPLDSFL RQREGQFSSL QLVAMQRGVA
     AAMQYLSSFA FVHRSLSAHS VLVNSHLVCK VARLGHSPQG PSCLLRWAAP EVIAHGKHTT
     SSDVWSFGIL MWEVMSYGER PYWDMSEQEV LNAIEQEFRL PPPPGCPPGL HLLMLDTWQK
     DRARRPHFDQ LVAAFDKMIR KPDTLQAGGD PGERPSQALL TPVALDFPCL DSPQAWLSAI
     GLECYQDNFS KFGLCTFSDV AQLSLEDLPA LGITLAGHQK KLLHHIQLLQ QHLRQQGSVE
     V
//
